HB 3714 appropriates $1,000,000 from Oklahoma's General Revenue Fund for the Barbara Weber ALS Grant Program during the 2026-2027 fiscal year. The funds will support the Oklahoma State Department of Health in administering grants to assist individuals diagnosed with Amyotrophic Lateral Sclerosis (ALS). The bill authorizes the use of these funds to cover program operations but does not establish new eligibility criteria or services. It becomes effective July 1, 2026, and includes an emergency clause for immediate implementation. This is a funding authorization for an existing program, not a new policy.
HB 3699 requires Oklahoma's Medicaid agency (OHCA) to seek federal approval for a supplemental reimbursement rate for physician practices, community health workers, and nonprofits already enrolled in Oklahoma's patient-centered medical home program. This rate specifically supports pediatric care for children from birth to age four, covering wellness visits and funding interdisciplinary staff needed to implement team-based care aligned with Bright Futures screening guidelines (at 9, 18, and 30 months). Providers must verify ongoing participation in evidence-based pediatric practice models through annual documentation. The bill mandates OHCA to periodically review the rate during future Medicaid physician service rate adjustments and takes effect November 1, 2026.
HB 1709 prohibits creditors and debt collectors from reporting debts related to lifesaving and emergency medical care at Oklahoma medical facilities to credit bureaus. It also bans credit bureaus from including such debts on consumer credit reports. This applies specifically to debts for emergency or life-threatening condition treatments at hospitals, nursing facilities, or licensed medical offices in Oklahoma. The law directly affects Oklahoma residents who receive emergency care, preventing these medical debts from negatively impacting their credit scores. The bill takes effect November 1, 2025.
HB 2945, the "Protecting Moms and Babies Act," prohibits manufacturing, distributing, mailing, transporting, prescribing, or providing abortion-inducing drugs in Oklahoma, with specific exceptions for medical treatments like ectopic pregnancy or miscarriage. It allows only private citizens (via "qui tam" lawsuits) to enforce the ban, not state officials, and explicitly prohibits lawsuits against pregnant women seeking abortion or common carriers transporting patients (if unaware of intent). The law defines "abortion-inducing drugs" to include medications like Mifeprex and misoprostol, excluding use for non-abortion medical purposes. Key exceptions permit the drug's use solely to preserve a mother's life, treat ectopic pregnancy, or address miscarriage-related complications.
SB 207 establishes the Oklahoma Rare Disease Advisory Council within the State Department of Health to address the needs of Oklahomans living with rare diseases (defined as conditions affecting fewer than 200,000 people nationally). The Council, composed of 13 diverse members including patients, caregivers, healthcare providers, researchers, and industry representatives, will conduct public hearings, develop policy recommendations, and create emergency care protocols to improve access to specialists, diagnostics, and equitable treatment. The bill also modifies Oklahoma’s newborn screening program to require an educational initiative for treatable genetic disorders, aiming to prevent intellectual disabilities and reduce infant mortality through early intervention. This legislation directly affects rare disease patients, their families, healthcare providers, and state agencies responsible for public health programs in Oklahoma.
SB 1039 modifies Oklahoma's medical marijuana licensing system. It establishes a new Oklahoma Medical Marijuana Authority to process applications, sets a $100 biannual fee (or $20 for Medicaid/Medicare/SoonerCare users) for patient licenses, and creates three license types: standard two-year licenses, 60-day short-term licenses for patients with limited physician recommendations, and 30-day temporary licenses for out-of-state patients from regulated states. The bill requires the Authority to review applications within 14 business days and provide written denial reasons, while also creating caregiver licenses for homebound patients with specific limits. This law directly affects Oklahoma residents seeking medical marijuana access, out-of-state visitors with valid programs, and caregivers.
HB 2513, titled the "Oklahoma Mental Health Reform Act of 2025," proposed creating a position requiring an individual with specific qualifications to address the Department of Mental Health and Substance Abuse Services' court-ordered consent decree. The bill specified requirements for this appointee and included an emergency provision. It was scheduled to take effect November 1, 2025, but was pocket-vetoed by the Governor on May 30, 2025, with the veto taking effect June 15, 2025, meaning it never became law. The bill directly affected the Department's compliance with its existing legal agreement but was not enacted.
HB 2645 creates a tax credit for qualifying doctors practicing medicine in rural Oklahoma, directly affecting licensed physicians who meet specific residency and education criteria. The credit, capped at $20,000 per year per doctor, applies to taxable income from medical practice in designated rural areas (population under 25,000 and at least 25 miles from larger cities). The bill includes an annual $1 million total credit limit, with adjustments to prevent exceeding this cap. The bill was pocket-vetoed by the governor on June 15, 2025, and never became law.
HB 2262 requires nursing homes, assisted living facilities, and other care providers marketing specialized dementia care to publicly disclose detailed information about their services. Facilities must submit a standardized form to Oklahoma's State Department of Health, covering staff ratios, care plans, facility design, activities, fees, and family involvement - ensuring transparency for residents and families considering placement. The bill mandates posting this disclosure online and in facilities, with the Department reviewing it during inspections. It directly affects dementia care providers and supports informed decisions by families seeking appropriate care.
HB 1576 requires Oklahoma Medicaid to cover rapid whole genome sequencing (RWGS) for eligible beneficiaries under age 21 with complex or acute illnesses of unknown cause while receiving critical care in a hospital. It mandates coverage only when specific medical criteria are met, such as symptoms suggesting broad genetic testing needs, timely diagnosis being critical for treatment, and conditions like congenital anomalies or abnormal test results. The bill also ensures genetic data used for diagnosis is protected under HIPAA, allows research use only with explicit patient or guardian consent (with opt-out rights), and requires the Oklahoma Health Care Authority to implement rules and seek federal approval for coverage. This policy directly affects Medicaid-covered children and teens in intensive care with undiagnosed conditions.
